We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals
IONS

367 hedge funds and large institutions have $5.62B invested in Ionis Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 110 increasing their positions, 129 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.42% less ownership

Funds ownership: 86.28% → 84.86% (-1.4%)

2% less funds holding

Funds holding: 375 → 367 (-8)

11% less call options, than puts

Call options by funds: $32.5M | Put options by funds: $36.6M

12% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 52

15% less repeat investments, than reductions

Existing positions increased: 110 | Existing positions reduced: 129

21% less capital invested

Capital invested by funds: $7.09B → $5.62B (-$1.47B)

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

Holders
367
Holders Change
-8
Holders Change %
-2.13%
% of All Funds
7.41%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.1%
New
46
Increased
110
Reduced
129
Closed
52
Calls
$32.5M
Puts
$36.6M
Net Calls
-$4.06M
Net Calls Change
+$1.92M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$118M
2
Citadel Advisors
Citadel Advisors
Florida
+$39.3M
3
BG
Bellevue Group
Switzerland
+$25.9M
4
Two Sigma Investments
Two Sigma Investments
New York
+$19M
5
Invesco
Invesco
Georgia
+$12.9M

Top Sellers

Rank Fund Capital Flow
1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$183M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$48M
3
BI
BVF Inc
California
-$38.2M
4
ClearBridge Investments
ClearBridge Investments
New York
-$21.6M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$17.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
CSPIA
326
Cary Street Partners Investment Advisory
Virginia
$5K +$5.55K +100 New
TFM
327
TFC Financial Management
Massachusetts
$5K +$5.67K +102 New
BCM
328
Blume Capital Management
California
$4K – – –
GWMIA
329
Global Wealth Management Investment Advisory
Florida
$4K – – –
GI
330
Gradient Investments
Minnesota
$4K – – –
ZB
331
Zions Bancorporation
Utah
$4K +$2.44K +44 +96%
FFA
332
Founders Financial Alliance
North Carolina
$4K +$4.44K +80 New
RA
333
Rational Advisors
New York
$4K +$4.94K +89 New
TPCW
334
TD Private Client Wealth
New York
$3.99K – – –
OSAM
335
O'Shaughnessy Asset Management
Connecticut
$3K -$14.3K -257 -79%
PWMG
336
Prestige Wealth Management Group
New Jersey
$3K – – –
RIM
337
Rockbridge Investment Management
New York
$3K – – –
TFS
338
TrustCore Financial Services
Tennessee
$3K – – –
AII
339
AGF Investments Inc
Ontario, Canada
$2K – – –
ABC
340
Associated Banc-Corp
Wisconsin
$2K – – –
BWA
341
BDO Wealth Advisors
Florida
$2K – – –
BFC
342
Bedel Financial Consulting
Indiana
$2K – – –
EARNEST Partners
343
EARNEST Partners
Georgia
$2K – – –
HIA
344
Harbor Investment Advisory
Maryland
$2K – – –
LWM
345
Liberty Wealth Management
California
$2K – – –
SBL
346
Sargent Bickham Lagudis
Colorado
$2K – – –
SFA
347
Semmax Financial Advisors
North Carolina
$2K – – –
TWA
348
TCI Wealth Advisors
Arizona
$2K – – –
VCM
349
Versant Capital Management
Arizona
$2K – – –
EI
350
Ellevest Inc
New York
$2K +$333 +6 +19%
12 13
14
15 16

IONS Hedge Fund Activity: Q3 2020 in Review

367 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2020, worth a combined $5.62B — down 21% from $7.09B a quarter earlier.

Sellers outnumbered buyers: 52 funds closed out of IONS and 46 opened new positions — a net loss of 6 holders — while 129 trimmed existing stakes and 110 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $118M. The largest seller was Baillie Gifford & Co, cutting an estimated $183M.

  • 367 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2020, down from 375 in Q2 2020.
  • Funds reported $5.62B of Ionis Pharmaceuticals stock for Q3 2020, down 21% quarter-over-quarter.
  • 46 funds opened new Ionis Pharmaceuticals positions in Q3 2020 and 52 closed out, a net change of -6 holders.
  • The largest Ionis Pharmaceuticals buyer in Q3 2020 was T. Rowe Price Associates, an estimated $118M added.
  • The largest Ionis Pharmaceuticals seller in Q3 2020 was Baillie Gifford & Co, an estimated $183M sold.

Based on aggregated 13F filings for Q3 2020.